| Window | Theses | Resolved | Wins | Win rate | Avg return | Median return |
|---|---|---|---|---|---|---|
| 1d | — | — | — | — | — | — |
| 3d | — | — | — | — | — | — |
| 1w | — | — | — | — | — | — |
| 1m | — | — | — | — | — | — |
| 3m | — | — | — | — | — | — |
| 6m | — | — | — | — | — | — |
| 1y | — | — | — | — | — | — |
Past performance does not predict future results. Informational only, not investment advice.
PCSA's 120-day deadline for finalizing a binding $454M licensing deal with Intact Therapeutics expires October 15th. Two of three likely outcomes (deal completion or extension with additional payment) are bullish, while a walk-away is least probable. The stock is consolidating on low volume in anticipation of this catalyst.
PCSA signed a binding term sheet with Intact Therapeutics for PCS12852 worth over $454M in potential milestone and royalty payments, creating a significant disconnect between the microcap's current valuation and upside if the deal closes and the drug progresses through trials and commercialization.
Stock exhibits a repeated intraday dip-and-rebound pattern with support holding on higher timeframes. The consistent absorption of dips and subsequent gap-ups suggest institutional buying, indicating further upside potential.
End of results.